Introduction – Company Background

GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.

With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.

With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.

From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.

At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.

By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.

Core Strengths in Insole Manufacturing

At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.

Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.

We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.

With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.

Customization & OEM/ODM Flexibility

GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.

Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.

With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.

Quality Assurance & Certifications

Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.

We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.

Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.

ESG-Oriented Sustainable Production

At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.

To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.

We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.

Let’s Build Your Next Insole Success Together

Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.

From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.

Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.

🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw

Pillow ODM design and manufacturing company in Taiwan

Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.

With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.Custom foam pillow OEM in Thailand

Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.

We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.Taiwan graphene material ODM solution

At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.Taiwan high-end foam product OEM/ODM

📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.Custom graphene foam processing China

Life appearance reconstruction of a Neanderthal male at the Natural History Museum of London. Credit: Allan Henderson, under CC BY 2.0 New study challenges the theory that Neanderthals originated after an evolutionary event that implied the loss of part of their genetic diversity. Neanderthals first appeared around 250,000 years ago, evolving from earlier European populations known as “pre-Neanderthals,” which lived across Eurasia between 500,000 and 250,000 years ago. For a long time, researchers believed Neanderthals underwent little significant evolutionary change. However, recent paleogenetic studies analyzing DNA from fossils have revealed a major loss of genetic diversity between early Neanderthals (also called “ancient Neanderthals”) and their later counterparts, known as “classic Neanderthals.” This genetic loss, known as a “bottleneck,” typically results from a sharp decline in population size. Paleogenetic evidence suggests that this event occurred around 110,000 years ago. Scientists had also widely assumed that an earlier bottleneck occurred at the origin of the Neanderthal lineage. As a result, previous hypotheses were based on the idea that the first Neanderthals had lower genetic diversity than their pre-Neanderthal ancestors due to an earlier population decline. Schematic representation of the changes in morphological diversity along the evolutionary history of the Neanderthal clade. Sima de los Huesos and, particularly, Krapina populations show similarly large amounts of morphological variation, thus suggesting continuity during the Middle Pleistocene. Later, classic Neanderthals instead appear much less diverse, hence hinting for the presence of a drop in phenotypic variation right after the temperature maximum reached around 120.000 years ago, and at the beginning of the Last Glacial cycle. Credit: Alessandro Urciuoli, Institut Català de Paleontologia Miquel Crusafont However, the existence of a bottleneck at the origin of the Neanderthals has not been confirmed yet through paleogenetic data, mainly due to the lack of genetic sequences old enough to record the event and needed for ancient DNA studies. New Insights from Inner Ear Morphology In a study led by Alessandro Urciuoli (Institut Català de Paleontologia Miquel Crusafont, Universitat Autònoma de Barcelona) and Mercedes Conde-Valverde (Cátedra de Otoacústica Evolutiva de HM Hospitales y la Universidad de Alcalá), researchers measured the morphological diversity in the structure of the inner ear responsible for our sense of balance: the semicircular canals. It is widely accepted that results obtained from studying the morphological diversity of the semicircular canals are comparable to those obtained through DNA comparisons. The study focused on two exceptional collections of fossil humans: one from the Sima de los Huesos site of Atapuerca (Burgos, Spain), dated to 430,000 years old, which constitutes the largest sample of pre-Neanderthals available in the fossil record; and another from the Croatian site of Krapina, this representing the most complete collection of early Neanderthals and dated to approximately 130.000-120.000 years ago. Artwork on the schematical representation of the distribution of morphological variation of the inner ear along time in Neanderthals. Credit: Alessandro Urciuoli, Institut Català de Paleop The researchers calculated the amount of morphological diversity (i.e., disparity) of the semicircular canals of both samples, comparing them with each other and with a sample of classic Neanderthals of different ages and geographical origins. Key Findings: Confirming and Challenging Previous Assumptions The study’s findings reveal that the morphological diversity of the semicircular canals of classic Neanderthals is clearly lower than that of pre-Neanderthals and early Neanderthals, which aligns with previous paleogenetic results. Mercedes Conde-Valverde, co-author of the study, emphasized the importance of the analyzed sample: “By including fossils from a wide geographical and temporal range, we were able to capture a comprehensive picture of Neanderthal evolution. The reduction in diversity observed between the Krapina sample and classic Neanderthals is especially striking and clear, providing strong evidence of a bottleneck event.” On the other hand, the results challenge the previously accepted idea that the origin of Neanderthals was associated with a significant loss of genetic diversity, prompting the need to propose new explanations for their origin. “We were surprised to find that the pre-Neanderthals from the Sima de los Huesos exhibited a level of morphological diversity similar to that of the early Neanderthals from Krapina,” commented Alessandro Urciuoli, lead author of the study. “This challenges the common assumption of a bottleneck event at the origin of the Neanderthal lineage,” the researcher stated. Reference: “Semicircular canals shed light on bottleneck events in the evolution of the Neanderthal clade” by Alessandro Urciuoli, Ignacio Martínez, Rolf Quam, Juan Luis Arsuaga, Brian A. Keeling, Julia Diez-Valero and Mercedes Conde-Valverde, 20 February 2025, Nature Communications. DOI: 10.1038/s41467-025-56155-8 Funding: MCIN/AEI, Generalitat de Catalunya, NextGenerationEU

Mirror life presents serious dangers, primarily due to its potential to interact unpredictably with the natural world. Without natural checks like predators or antibiotics, mirror organisms could replicate uncontrollably, creating risks that scientists are only beginning to understand. Credit: SciTechDaily.com Mirror life, a concept involving synthetic organisms with reversed molecular structures, carries significant risks despite its potential for medical advancements. Experts warn that mirror bacteria could escape natural biological controls, potentially evolving to exploit resources in ways that disrupt ecosystems and pose unforeseen dangers to the environment and public health. Mirror Life “Mirror life” refers to synthetic organisms with molecular structures reversed from those found in natural life. At first glance, creating such life forms seems impossible—and for now, it is. Even the simplest mirror bacterium would be far too complex for scientists to build with current technology. However, the idea of mirror life may not remain purely theoretical. Rapid advancements in biotechnology could make its creation possible within the next few decades. If realized, mirror-image bacteria could revolutionize drug development, offering groundbreaking medical treatments. But they could also pose serious environmental risks, behaving in unpredictable and potentially harmful ways. Michael Kay, MD, PhD, a biochemistry professor at the Spencer Fox Eccles School of Medicine at the University of Utah and an expert in mirror-image pharmaceuticals, explains the science behind mirror life—and why he believes it should remain hypothetical. The Concept of Biological Chirality To talk about mirror life, I need to first talk about regular life. All of the biomolecules that make up life, like DNA and proteins, have a handedness to them, just like your hands. They could, in theory, come in a left-handed or a right-handed version. Billions of years ago, life on Earth standardized on left-handed proteins. All life that evolved from that has continued to use left-handed proteins. So when we’re talking about mirror-image life, it’s kind of like a “what if” experiment: What if we constructed life with right-handed proteins instead of left-handed proteins? Something that would be very, very similar to natural life, but doesn’t exist in nature. We call this mirror-image life or mirror life. This type of life would only exist if it was made synthetically. Potential Applications in Medicine We’re one of the leading groups that is interested in this, and our interest is largely in mirror-image therapeutics. If you give therapeutics to a person, especially protein or nucleic acid therapeutics, digestive enzymes in the body break them down rapidly, sometimes within minutes. This can make it very challenging to treat chronic illnesses in a way that’s cost-effective and convenient. But mirror molecules are not recognized by those digestive enzymes, so they have the potential to last for a much longer period of time and to open up a whole new class of therapeutics that would allow us to treat a variety of diseases that are currently challenging. Currently, we make mirror therapeutics chemically, stitching them together atom by atom. If we had mirror bacteria, which could make these for us, that could be a route to much more efficient large-scale production of mirror therapeutics. Mirror biology can be used to create long-lasting therapeutics. Importantly, mirror molecules that are created chemically cannot self-replicate, and therefore pose none of the risks of a mirror bacterium. Credit: Judah Evangelista / Kay Lab. The Risks of Synthetic Organisms A mirror organism would interact with the rest of our world in unpredictable, uncertain ways. There is a plausible threat that mirror life could replicate unchecked, because it would be unlikely to be controlled by any of the natural mechanisms that prevent bacteria from overgrowing. These are things like predators of the bacteria that help to keep it under control, antibiotics and the immune system, which are not expected to work on a mirror organism, and digestive enzymes. There is a real possibility that mirror bacteria would struggle to find enough food to eat in order to grow, but we are humble in the face of evolution. If these bacteria are able to grow at all—and there is evidence that they probably would be able to grow, at least to some extent, in our natural world—maybe, over time, they could evolve the ability to eat our food and convert it to mirror food. If that happened, that would release a brake on their growth, and then all these other controlling mechanisms, as far as we can tell, would not be effective against these mirror bacteria. But there’s a lot of uncertainty in this determination. At this point, we don’t have enough information to make a definitive estimate of what the risk would be. Technological Horizons and Future Possibilities What’s really critical is that people know there isn’t an imminent risk. We’ve never built something even close to as complex as an entire bacterial cell. It’s incredibly difficult, and new technologies are still needed to do that in a sufficiently efficient way. But we’re in a very exciting period in synthetic biology right now where new technologies, chemical synthesis, and minimal cell development are moving fast, which is why we thought this was a good time to really have this discussion as those foundational technologies are starting to develop and emerge. I think the best time estimate we have is that we’re probably one to three decades away from something like this being possible, if we made the decision to make this a priority. It would take tremendous resources and the cooperation of a huge consortium of international scientists with specialties in different aspects of cell construction. This is definitely not going to happen overnight. But it’s not so far into the future that we think that it’s something we can just hope won’t happen for a while. Mitigating Risks and Planning Ahead We hope that this commentary will kick off extensive discussions on this topic with a broad group of stakeholders. We plan to start having international conferences in the coming year to discuss the risks and work with international agencies to develop a regulatory framework that would allow us to prevent those risks. This wouldn’t affect anybody’s current research. We think there’s an opportunity, before anyone’s livelihood depends on this, to define responsible lines of research, lines that should be carefully evaluated by regulatory authorities, and the lines we shouldn’t cross. It’s important to differentiate between mirror life and benign uses of mirror technology which are already underway. Mirror drugs are in development right now, including by our lab. Because these are chemically made, there is no risk of them posing any of the dangers that exclusively come with making a self-replicating mirror bacteria. Once a mirror cell is made, it’s going to be incredibly difficult to try to put that genie back in the bottle. That’s a big motivation for why we’re thinking about prevention and regulation well ahead of any potential actual risk. Reference: “Confronting risks of mirror life” by Katarzyna P. Adamala, Deepa Agashe, Yasmine Belkaid, Daniela Matias de C. Bittencourt, Yizhi Cai, Matthew W. Chang, Irene A. Chen, George M. Church, Vaughn S. Cooper, Mark M. Davis, Neal K. Devaraj, Drew Endy, Kevin M. Esvelt, John I. Glass, Timothy W. Hand, Thomas V. Inglesby, Farren J. Isaacs, Wilmot G. James, Jonathan D. G. Jones, Michael S. Kay, Richard E. Lenski, Chenli Liu, Ruslan Medzhitov, Matthew L. Nicotra, Sebastian B. Oehm, Jaspreet Pannu, David A. Relman, Petra Schwille, James A. Smith, Hiroaki Suga, Jack W. Szostak, Nicholas J. Talbot, James M. Tiedje, J. Craig Venter, Gregory Winter, Weiwen Zhang, Xinguang Zhu and Maria T. Zuber, 12 December 2024, Science. DOI: 10.1126/science.ads9158 A commentary by Kay and other experts is published in Science as “Confronting risks of mirror life.” Banner image has been modified and is credit NIAID.

In this colon tumor, which has a mutation that gives it a high degree of DNA mismatch repair deficiency, T cells (labeled black, green, and red) have accumulated primarily in the supportive tissues (pink regions), while very few have infiltrated tumor cells (islands surrounded by the supportive tissues). Credit: Courtesy of the researchers The findings could help doctors identify cancer patients who would benefit the most from drugs called checkpoint blockade inhibitors. Cancer drugs known as checkpoint blockade inhibitors have proven effective for some cancer patients. These drugs work by taking the brakes off the body’s T cell response, stimulating those immune cells to destroy tumors. Some studies have shown that these drugs work better in patients whose tumors have a very large number of mutated proteins, which scientists believe is because those proteins offer plentiful targets for T cells to attack. However, for at least 50 percent of patients whose tumors show a high mutational burden, checkpoint blockade inhibitors don’t work at all. A new study from MIT reveals a possible explanation for why that is. In a study of mice, the researchers found that measuring the diversity of mutations within a tumor generated much more accurate predictions of whether the treatment would succeed than measuring the overall number of mutations. If validated in clinical trials, this information could help doctors to better determine which patients will benefit from checkpoint blockade inhibitors. Key Insights “While very powerful in the right settings, immune checkpoint therapies are not effective for all cancer patients. This work makes clear the role of genetic heterogeneity in cancer in determining the effectiveness of these treatments,” says Tyler Jacks, the David H. Koch Professor of Biology and a member of MIT’s Koch Institute for Cancer Research. Jacks; Peter Westcott, a former MIT postdoc in the Jacks lab who is now an assistant professor at Cold Spring Harbor Laboratory; and Isidro Cortes-Ciriano, a research group leader at EMBL’s European Bioinformatics Institute (EMBL-EBI), are the senior authors of the paper, which was published on September 14 in the journal Nature Genetics. Diversity in Mutations Across all types of cancer, a small percentage of tumors have what is called a high tumor mutational burden (TMB), meaning they have a very large number of mutations in each cell. A subset of these tumors has defects related to DNA repair, most commonly in a repair system known as DNA mismatch repair. Because these tumors have so many mutated proteins, they are believed to be good candidates for immunotherapy treatment, as they offer a plethora of potential targets for T cells to attack. Over the past few years, the FDA has approved a checkpoint blockade inhibitor called pembrolizumab, which activates T cells by blocking a protein called PD-1, to treat several types of tumors that have a high TMB. However, subsequent studies of patients who received this drug found that more than half of them did not respond well or only showed short-lived responses, even though their tumors had a high mutational burden. The MIT team set out to explore why some patients respond better than others, by designing mouse models that closely mimic the progression of tumors with high TMB. These mouse models carry mutations in genes that drive cancer development in the colon and lung, as well as a mutation that shuts down the DNA mismatch repair system in these tumors as they begin to develop. This causes the tumors to generate many additional mutations. When the researchers treated these mice with checkpoint blockade inhibitors, they were surprised to find that none of them responded well to the treatment. “We verified that we were very efficiently inactivating the DNA repair pathway, resulting in lots of mutations. The tumors looked just like they look in human cancers, but they were not more infiltrated by T cells, and they were not responding to immunotherapy,” Westcott says. Intratumoral Heterogeneity The researchers discovered that this lack of response appears to be the result of a phenomenon known as intratumoral heterogeneity. This means that, while the tumors have many mutations, each cell in the tumor tends to have different mutations than most of the other cells. As a result, each individual cancer mutation is “subclonal,” meaning that it is expressed in a minority of cells. (A “clonal” mutation is one that is expressed in all of the cells.) In further experiments, the researchers explored what happened as they changed the heterogeneity of lung tumors in mice. They found that in tumors with clonal mutations, checkpoint blockade inhibitors were very effective. However, as they increased the heterogeneity by mixing tumor cells with different mutations, they found that the treatment became less effective. “That shows us that intratumoral heterogeneity is actually confounding the immune response, and you really only get the strong immune checkpoint blockade responses when you have a clonal tumor,” Westcott says. Failure to Activate It appears that this weak T cell response occurs because the T cells simply don’t see enough of any particular cancerous protein, or antigen, to become activated, the researchers say. When the researchers implanted mice with tumors that contained subclonal levels of proteins that normally induce a strong immune response, the T cells failed to become powerful enough to attack the tumor. “You can have these potently immunogenic tumor cells that otherwise should lead to a profound T cell response, but at this low clonal fraction, they completely go stealth, and the immune system fails to recognize them,” Westcott says. “There’s not enough of the antigen that the T cells recognize, so they’re insufficiently primed and don’t acquire the ability to kill tumor cells.” To see if these findings might extend to human patients, the researchers analyzed data from two small clinical trials of people who had been treated with checkpoint blockade inhibitors for either colorectal or stomach cancer. After analyzing the sequences of the patients’ tumors, they found that patients’ whose tumors were more homogeneous responded better to the treatment. Conclusion and Implications “Our understanding of cancer is improving all the time, and this translates into better patient outcomes,” Cortes-Ciriano says. “Survival rates following a cancer diagnosis have significantly improved in the past 20 years, thanks to advanced research and clinical studies. We know that each patient’s cancer is different and will require a tailored approach. Personalized medicine must take into account new research that is helping us understand why cancer treatments work for some patients but not all.” The findings also suggest that treating patients with drugs that block the DNA mismatch repair pathway, in hopes of generating more mutations that T cells could target, may not help and could be harmful, the researchers say. One such drug is now in clinical trials. “If you try to mutate an existing cancer, where you already have many cancer cells at the primary site and others that may have disseminated throughout the body, you’re going to create a super heterogeneous collection of cancer genomes. And what we showed is that with this high intratumoral heterogeneity, the T cell response is confused and there is absolutely no response to immune checkpoint therapy,” Westcott says. For more on this research, see Why Does Immunotherapy Not Always Work? Reference: “Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity” by Peter M. K. Westcott, Francesc Muyas, Haley Hauck, Olivia C. Smith, Nathan J. Sacks, Zackery A. Ely, Alex M. Jaeger, William M. Rideout III, Daniel Zhang, Arjun Bhutkar, Mary C. Beytagh, David A. Canner, Grissel C. Jaramillo, Roderick T. Bronson, Santiago Naranjo, Abbey Jin, J. J. Patten, Amanda M. Cruz, Sean-Luc Shanahan, Isidro Cortes-Ciriano and Tyler Jacks, 14 September 2023, Nature Genetics. DOI: 10.1038/s41588-023-01499-4 The research was funded by the Koch Institute Support (core) Grant from the U.S. National Cancer Institute, the Howard Hughes Medical Institute, and a Damon Runyon Fellowship Award.

DVDV1551RTWW78V